AQUAPASS Completes Enrollment in REFORM-HF Pivotal Trial, Results to Be Presented at Major Heart Failure Conference This Fall
NEWTON, Mass. and SHEFAYIM, Israel, Aug. 10, 2026 /PRNewswire/ -- AQUAPASS, developer of a noninvasive, kidney-independent therapy for fluid overload management in patients experiencing heart failure and chronic or end-stage kidney disease, announced completion of enrollment in its FDA...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Cuvo Health Publishes 2026 State-by-State Virtual Clinic Compliance Report: 33 of 51 Jurisdictions Restrict the Corporate Practice of Medicine
- Envision Energy získala certifikát TÜV SÜD pro řídicí systém větrných elektráren. Posiluje tak dlouhodobou odolnost budoucích energetických systémů
- 美国参议员 Tillis 与 Padilla 提出法案，加快针对全美首要死因的研究
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →